One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Second Sight’s second product might lead the company to second place in the market.
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.